EQL Pharma AB (publ) announced that the company's long-term financial goals remain unchanged, as does the sales forecast for the full year 2023/24, where they forecast growth of around 30%.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.9 SEK | -0.68% | +1.15% | +31.44% |
04-22 | EQL Pharma AB Announces Mellozzan Launched in Germany and Austria | CI |
02-13 | EQL Pharma AB Provides Sales Guidance for the Year 2023/24 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+31.44% | 118M | |
-33.55% | 14.97B | |
-26.34% | 11.95B | |
-28.54% | 6.27B | |
+13.49% | 6.36B | |
-10.03% | 6.12B | |
0.00% | 4.75B | |
+64.00% | 4.58B | |
-8.64% | 3.84B | |
-10.56% | 3.51B |
- Stock Market
- Equities
- EQL Stock
- News EQL Pharma AB
- EQL Pharma AB Provides Sales Guidance for the Year 2023/24